Introduction
The question if and when patients undergoing allogeneic stem cell transplantation (ASCT) should be transferred to an intensive care unit (ICU) is controversial. Several variables have been associated with mortality in ASCT patients transferred to the ICU. Most common are patients requiring mechanical ventilation, multiorgan failure and shock. 1 Despite the poor prognosis, survival after ICU care has been reported. [2] [3] [4] Since 1998, the survival of ASCT patients treated in the ICU has improved, probably attributed to improvements in ASCT treatment, patient selection and ICU management. 1 At the ICU, more sophisticated ventilation strategies have been developed, 5 such as invasive and noninvasive ventilation (NIV), and early goal-directed therapy (EGDT). 6 The latter means that patients should be stabilized to normal physiological level as soon as possible at the ICU. Reduced-intensity conditioning (RIC) regimens before ASCT have resulted in less toxicity. 7 Molecular monitoring, more effective prophylaxis and preemptive treatment strategies of various infections have been developed during the past decade, improving survival after ASCT. 8, 9 Traditional prognostic systems such as acute physiological and chronic health evaluation (APACHE) have shown limited value in ASCT patients. 1 APACHE II underestimated survival in patients with scores less than 35, and could only be used to predict 100% mortality when it exceeded 45. 10 Sequential Organ Failure Assessment (SOFA) showed good correlation to prognosis in other patient groups. [11] [12] [13] The primary aim of this study was to analyze the incidence and outcome of all ASCT patients transferred to the ICU at our center between 1995 and 2005. The secondary aim was to find a tool to monitor the prognosis of ASCT patients admitted to the ICU. A valid prognostic factor for these patients may be useful in deciding whether an ICU treatment should be started and also whether ICU therapy should be discontinued in deteriorating patients.
Patients and methods

Patients
A total of 661 patients received ASCT at Karolinska University Hospital, Huddinge between 1 January 1995 and 31 December 2005. Of them, 91 patients (14%) were admitted to the ICU during this period, and 4 patients were transferred to the ICU twice. The diagnoses for patients admitted to the ICU were hematological malignancies (n ¼ 65), solid tumors (n ¼ 7) and non-malignant diseases (n ¼ 9). Twenty-six patients (29%) were younger than 18 years of age at the time of ASCT. Patient and donor characteristics are shown in Table 1 .
Conditioning
A majority of patients received myeloablative conditioning (n ¼ 72). The myeloablative conditioning regimens consisted of CY (60 mg/kg daily) for 2 days in combination with either 10 Gy single-dose TBI or 12 Gy (4 Â 3 Gy) of fractionated TBI, or BU (4 mg/kg per day, divided in 4 doses). Nineteen patients received RIC.
14 Sixty-three patients (69%) were treated with antithymocyte globulin (ATG) Thymoglobulin; Genzyme, Cambridge, MN, USA), for 3-5 days at a total dose of 4-8 mg/kg. 15 
GVHD prophylaxis
A total of 73 patients received a combination of CsA and MTX as GVHD prophylaxis. 16, 17 In the absence of GVHD, CsA was discontinued after 6 months for patients who received a matched unrelated donor or mismatched grafts, and after 3-4 months in the case of sibling transplantations. 18 For patients with non-malignant disease, immunosuppressive treatment was discontinued within 2 years.
Supportive care
During the pancytopenic phase, all patients received prophylactic treatment with oral ciprofloxacin (500 mg twice daily), fluconazole (100 mg daily) and nystatin (200 000 IU, 4 times daily) until ANC exceeded 0.5 Â 10 9 / liter. Details regarding supportive care were published earlier. 8 
ICU scoring systems
Patients younger than 15 years were not included in the analysis concerning ICU scoring systems. To monitor the patients at the ICU, the APACHE II and the SOFA scores were used. The SOFA score assesses the function of six different organ systems: respiratory (partial arterial oxygen pressure (PaO 2 )/fraction of inspired oxygen (FiO 2 )), cardiovascular (blood pressure, vasopressor use), renal (creatinine and diuresis), hepatic (bilirubin), neurological (Glasgow Coma Score) and hematological (platelet count). Normally, it was calculated once daily using the most abnormal data from the preceding 24 h and given a score from 0 (normal) to 4 (most abnormal) in each organ system. 19 SOFA and APACHE II scores were calculated retrospectively for the first day at the ICU using the initial blood samples and patient clinical status at ICU arrival.
ICU treatment
The ventilation used at the ICU was distributed in three groups. All patients with spontaneous breathing, only needing extra oxygen, were classified as spontaneous breathing. In the group with NIV, the most common ventilation mode was continuous positive airway pressure (CPAP) with assisted spontaneous breathing (CPAP-ASB). In the beginning of the studied period, pure CPAP without pressure assist was used. In the past years, CPAP was replaced by CPAP-ASB in our ICU. The third group, invasive ventilation, was defined by an intubation. In the beginning of the 11-year period studied, the dominating ventilation mode was continuous positive pressure ventilation, which has been replaced by more lung-protective ventilation strategies such as BiPAB and CPAP-ASB. The ventilation strategies with lower tidal volumes as recommended in the study from the ARDS network were implemented. 5 A few patients received airway pressure release ventilation (APRV).
As vasopressor/inotropy, norepinephrine was used alone or in combination with epinephrine. Circulatory monitoring was performed with measurement of the arterial blood pressure and central venous pressure. In the past years, transthoracic echocardiography was used to judge the cardiac output and volume status. 
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Fluid and volume substitution was initially performed by albumin (4 and 20%); in the past years, albumin was replaced by synthetic colloids such as hydroxyethylstarch. As crystalloid administration, Ringeracetat was used. If needed, continuous venovenous hemodiafiltration (CVVHDF) was used as renal replacement therapy. All patients transferred to the ICU who needed respiratory support were classified as a respiratory failure, and patients with bacteremia and symptoms such as circulatory instability, signs of systemic inflammation and disseminated intravasal coagulation were classified as septic shock.
Statistics
Analysis was performed in September 2006. Survival rates (death at ICU or within 30 days after discharge from ICU) were calculated using the method of Kaplan-Meier and compared with the log-rank method. In the four patients treated twice at the ICU, only the last treatment period was counted. In the multivariate analysis of factors associated with death at the ICU, the Cox regression method was used. Death at the ICU or within 30 days after discharge from the ICU was a censoring variable and time from admittance to the ICU until death or last follow-up was calculated. A step-wise backward procedure was used to construct a set of independent predictors for death at the ICU. All predictors with a P-value below 0.10 were considered and sequentially removed if the P-value in the multiple models was above 0.05. All tests were two sided. The type I error rate was fixed at 0.05 for factors potentially associated with time-to-event outcome. Analyses were performed using the Statistica software (Tulsa, OK, USA).
Results
Reasons for ICU admission A total of 39 patients (41%) were admitted because of respiratory failure, and 29 patients (31%) because of septic shock (Table 2) . Eleven patients (12%) were transferred to the ICU after neurological events such as seizures and intracerebral bleeding.
Transplant-related complications at transfer to ICU Acute GVHD grades II-IV were diagnosed in 44 patients (48%) before admission to the ICU. The majority (92%) of the transferred patients also received immunosuppressive treatment (Table 3) . Ten patients had veno-occlusive disease (VOD) of the liver. Bacteremia was diagnosed in 54 patients (59%) before ICU treatment and 95% of the patients received antibiotics at admission or after admission to the ICU (Table 3) . A majority of patients were also treated with antifungal and antiviral drugs. During ICU treatment, the majority of patients were transfusion dependent as shown in Table 3 .
ICU treatment
Patients were admitted to the ICU median 69 (À24 to 1572) days after ASCT. One patient was at the ICU already before ASCT. The median stay at the ICU was 4 (1-60) days. During the ICU treatment, five patients required renal replacement therapy with CVVHDF. Vasoactive and/ or inotropic agent support was used in 55 cases (58%) ( Table 3 ).
Respiration treatment
Twenty-two patients (23%) were given inhalation of oxygen up to 15 liter/min (FiO 2 1.0) presented by mask. In the beginning of the study period, NIV was not developed. Therefore, intubation had to be performed if treatment with inhalation of oxygen was not successful. In the later years, respiratory support was in most cases Table 2 Reasons for transfer to the ICU started with NIV. Twenty-seven patients (29%) remained on NIV because of successful therapy or in some cases because of the active decision not to perform an intubation owing to the poor prognosis of the actual patient. Forty-six patients (48%) underwent intubation (Table 3) . Patients without respiratory support had a survival of 32%, compared with 20% (P ¼ 0.28) in patients needing mechanical ventilation. For patients with mechanical ventilation, survival was 15% before and 24% (NS) after the year 2000. For patients without respiratory support, survival was 25 and 41% (NS), respectively.
Prognostic scoring systems
The median APACHE II score for the first 24 h at admission to the ICU was 19 . Patients with adjusted predicted death rate p20 showed significantly better survival compared with patients with APACHE score 420 (53 vs 20%, P ¼ 0.004), illustrated in Figure 1 . The median SOFA score for the first 24 h after admission to the ICU was 10 (1-17). Patients with SOFA o8 showed a cumulative survival of 44% compared with 17% in patients with SOFA 8-11. None of the 20 patients admitted to the ICU with SOFA score 411 survived (P ¼ 0.0002; Figure 2 ).
Survival
Fifty-three patients died during their ICU admission and an additional 14 patients (15%) within 1 month after discharge from the ICU. Twenty-eight (30%) patients survived more than 1 month after discharge from the ICU. At 100 days and 1 year after admission to the ICU, 22 and 16%, respectively, were alive ( Figure 3 ).
There was a trend for better survival among children (o18 years) compared with adults (46 vs 18%, P ¼ 0.07).
Patients needing vasoactive agents showed a lower survival compared with patients without vasopressor support (18 vs 43%, P ¼ 0.01; Figure 4a ). Patients who needed ICU treatment after retransplantation (either allogeneic or autologous) showed a poor prognosis. None of the 14 retransplanted patients survived compared with 31% among patients after first SCT (P ¼ 0.006; Figure 4b ). Patients receiving TBI-based pretreatment showed significantly lower survival compared with patients receiving chemotherapy, 14 vs 45% survival at 2 months after discharge from ICU (P ¼ 0.01; Figure 4c ). Reasons for ICU admission did not show any impact on survival as shown in Figure 5 .
Thirty-five patients (38%) were admitted to the ICU more than 100 days after ASCT. Survival for these patients did not differ from patients admitted to the ICU within 100 days after ASCT (20 vs 30%, P ¼ 0.54).
Multivariate analysis
In the multivariate analysis of factors associated with death at the ICU or within 30 days after discharge from the ICU, only the SOFA score remained significant (RH, 1.18; CI, 1.10-1.27; Po0.001). SOFA predicts outcome of ICU care after SCT K Gilli et al
Discussion
The indication for the use of ICU treatment and invasive ventilation for patients undergoing ASCT has been discussed since decades. Earlier studies have questioned whether patients after ASCT should even be transferred to the ICU for mechanical respiratory support. 2, 10, [20] [21] [22] However, in more recent studies, a better prognosis for ASCT recipients has been shown. 1, 3, 23, 24 This is probably because of improved therapy. 1, 4, 9, 25 The development of new respiratory strategies has improved the outcome of ICU patients with ARDS and respiratory failure. 5 This may be one reason for the improved outcome of ASCT recipients in the ICU. Other reasons for improved survival may involve less toxic conditioning regimens, better treatment of infectious complications and other transplant-related complications such as VOD and improved supportive care for visceral organ injury. 1, 9, 17 Patients admitted to the ICU who received TBI in the conditioning regimen did worse compared with patients receiving chemotherapy as conditioning. However, in an earlier randomized study by the Nordic Bone Marrow Transplantation group, a comparison of TBI/CY with BUCY showed that the latter was more toxic with more VOD, chronic GVHD and obstructive bronchiolitis. 26 In several earlier studies, the incidence and fatalities of interstitial pneumonia after ASCT were similar between TBI/CY and BUCY. 27, 28 The most plausible explanation may be that TBI is given above all to patients with acute lymphocytic leukemia, in most cases heavily treated before ASCT.
In an earlier study by Kew et al., 23 the probability of survival for patients receiving vasopressor support was 5% at 30 days compared with 76.5% survival in patients not given vasopressor support. This was also recently shown by Trinkaus et al. 29 in patients after autologous SCT. The need for vasopressors may therefore be a useful prognostic tool in identifying ASCT patients with poor survival. Indeed, in this study, patients with vasopressor support showed a worse survival (15%) compared with patients without vasoactive agents (41%). depending on the reason for ICU transfer. Four patients were treated twice at the ICU. These patients were treated as alive until they were admitted to the ICU for the second time. The second ICU treatment period was calculated from the second ICU admittance until death or the last follow-up. Only death at the ICU or within 30 days after discharge from the ICU was counted.
No patient receiving a second ASCT and admitted to the ICU survived. Second transplantation has earlier been associated with high transplant-related mortality, although patients of young age (o16 years), those with absence of GVHD and patients with late relapse (412 months) do better. 30 In this study, retransplantation indicates a poor prognosis in patients transferred to the ICU and may be included in deciding whether ICU treatment should be applied.
We found a primary ICU survival of ASCT patients of 44% and a 30-day survival of 29%. The 1-year survival was still poor with 16% but comparable with other studies in ASCT recipients. 1, 3, 23, 24 However, the results of treating ASCT patients in the ICU are poor in comparison with ICU treatment of non-transplanted patients, with a 1-year survival of 95% for patients with ICU treatment less than 5 days. 31 In accordance with Jackson et al., 10 we found an underestimation of the mortality in this patient group by APACHE II. Instead, SOFA predicted mortality of ASCT patients admitted to the ICU. The importance of SOFA as a prognostic tool was also recently shown in patients after autologous SCT. 29 Our study is also concordant with the results of Silfvast et al. 32 in which all patients with hematological malignancies transferred to the ICU with an SOFA score exceeding 11 died in the hospital. We found an even higher significance (P ¼ 0.0002) and 100% mortality with a SOFA score above 11 during the first day at the ICU. With a SOFA score of 8-11, the mortality was 83% compared with 56% in patients with SOFAo8. Therefore, a consultation with ICU physicians may be considered before patients reach a SOFA of 8. For patients with an SOFA score above 11, ICU care may not be an option.
There are several limitations in this study. This is a retrospective study without any stipulated criteria for ICU admission. There may have been considerable variation among ASCT and ICU physicians in considering and accepting ICU referrals. Moreover, this study only analyzed the patients transferred to the ICU and did not include the other 570 patients transplanted during this period. Many patients with poor prognosis were not considered for ICU treatment. However, SOFA may be helpful in deciding whether a critically ill ASCT patient may be transferred to the ICU.
Just as EGDT dramatically improved the treatment of septicemia with a decrease in mortality 6 years ago, an earlier onset of ICU care may increase the survival for critically ill ASCT patients. 33, 34 Most declining ASCT patients are referred for palliative care because of their expected poor outcome in the ICU. Therefore, transplant physicians should liaise closely with intensivists to ensure that ICU care is implemented as early as possible. The SOFA score may help in the difficult decision as to which patient may benefit from ICU care and also in initiating early discussions concerning advance directives and end-oflife care.
